Mark T. Fleming

基本信息

Career Trajectory

Bio

Cancers of the Bladder, Kidney, Prostate and Testicle as well as Phase 1 novel drug development are Dr. Fleming’s special clinical interest and expertise. He is heavily involved in cancer research serving as a principal investigator for clinical trials, locally and nationally, collaborating with institutions like Duke University Network, Hoosier Oncology Group, Prostate Cancer Clinical Trials Consortium and The US Oncology Research to provide the latest treatment options to patients.

Research Interests

Papers共 81 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

1970MO Circulating Tumor DNA (ctdna) Clearance with Neoadjuvant Durvalumab (D) + Tremelimumab (T) + Enfortumab Vedotin (EV) for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC) from the Safety Run-in Cohort of the Phase III VOLGA Trial

A. Drakaki,T.B. Powles, Y. Wang,M. Bupathi, M. Joshi,M.T. Fleming,A. Gomez de Liano Lista,R. Morales Barrera,R. Pili, S. Boulos,Y. Shrestha

Annals of Oncology (2024): S1140

Cited0Views0Bibtex

Karim Fizazi,Michael J. Morris,Neal D. Shore,Kim N. Chi,Michael Crosby,Johann S. De Bono,Ken Herrmann,Guilhem Roubaud,James Nagarajah,Mark T. Fleming,Brian E. Lewis,Luke Nordquist,Daniel Castellano, Natalie Carnahan,Samson Ghebremariam, Marianna Hertelendi,Oliver Sartor

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

1599P Symptomatic Skeletal Events, Health-Related Quality of Life and Pain in a Phase III Study of [177Lu]lu-Psma-617 in Taxane-Naive Patients with PSMA-positive Metastatic Castration-Resistant Prostate Cancer: Third Interim Analysis of PSMAfore

K. Fizazi,M.J. Morris,N.D. Shore,K.N. Chi,M. Crosby,J.S. de Bono,K. Herrmann,G. Roubaud,J. Nagarajah,M.T. Fleming, B. Lewis,L.T. Nordquist,D.E. Castellano Gauna, N. Carnahan,S. Ghebremariam, M. Hertelendi,O. Sartor

Annals of Oncology (2024): S964-S965

Cited0Views0Bibtex

The Impact of an Inclusion Council in an Independent Community Oncology Practice

Mark T. Fleming,Kristina Lyons,Roshonda Poole, Margot Richards, Sonia Hepburn, Tahj Ali-Spencer, Tifany Lewis

Journal of Clinical Oncologyno. 16_suppl (2024): e21018-e21018

Cited0Views0Bibtex

Infigratinib Versus Placebo in Patients with Resected Urothelial Cancer (UC) Bearing FGFR3 Mutation or Fusion: Primary DFS Analysis from the Phase 3, Randomized PROOF302 Study

Sumanta Kumar Pal,Petros Grivas,Shilpa Gupta,Begona Perez Valderrama,Alejo Rodriguez-Vida,Florian Roghmann,Elena Sevillano,Surena F. Matin,Yohann Loriot,Srikala S. Sridhar,Guru P. Sonpavde,Mark T. Fleming,Seth P. Lerner,Joaquim Bellmunt,Viraj A. Master,Abhishek Tripathi, Kim Davis, David Friedrich Van Veenhuyzen, Richard Weng,Siamak Daneshmand

JOURNAL OF CLINICAL ONCOLOGYno. 4_SUPPL (2024): 629-629

Cited0Views0Bibtex

True-Positive18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study

Mark T. Fleming,Rick Hermsen,Andrei S. Purysko,Albert Chau,Phillip Davis,Brian F. Chapin,David M. Schuster

Journal of Nuclear Medicineno. 7 (2024): 1080-1086

Cited0Views0WOSBibtex

Supplementary Table 3 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

Johann S. de Bono,Mark T. Fleming,Judy S. Wang,Richard Cathomas,Manuel Selvi Miralles,John Bothos,Mary Jane Hinrichs,Qu Zhang,Peng He,Marna Williams,Anton I. Rosenbaum,Meina Liang,Kapil Vashisht,Song Cho,Pablo Martinez,Daniel P. Petrylak

crossref（2023）

Cited0Views0Bibtex

Supplementary Figure 2 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

crossref（2023）

Cited0Views0Bibtex

Supplementary Table 2 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with Mcrpc after Failure of Abiraterone or Enzalutamide

crossref（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Founder

Papers共 81 篇Author StatisticsCo-AuthorSimilar Experts